Photobiomodulation therapy in age-related macular degeneration

Muste, Justin; Kalur, Aneesha; Iyer, Amogh; Valentim, Carolina C S; Singh, Rishi P.

doi:10.1097/icu.0000000000000742

Cited by 8 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 9 , 16 Photic stimulation uncouples nitric oxide, which would otherwise inhibit complex IV, thereby indirectly increasing mitochondrial activity. 12 , 14 , 17 The freed nitric oxide also triggers downstream cascades to increase anti-antioxidant production, anti-apoptotic pathways, and cellular metabolism. 18 Within photoreceptors, these changes amount to globally improved photoreceptor performance as measured by ATP production and electroretinogram (ERG).…”

Section: Discussionmentioning

confidence: 99%

“…In PBT, near-infrared spectral light (660-1000 nm) induces a photochemical reaction on the cellular level, starting with complex IV in the electron transport chain. [9][10][11][12][13][14] Complex IV colocalizes to retinal layers rich in mitochondria such as the nerve fiber layer, around retinal ganglion cell nuclei, the inner/outer plexiform layers, the photoreceptor inner segment and basal surface of retinal pigment epithelium (RPE) cells. 15 Complex IV is directly activated by NIR light, increasing respiratory chain function and mitochondrial activity.…”

Section: Mechanism Of Actionmentioning

confidence: 99%

“…18 Within photoreceptors, these changes amount to globally improved photoreceptor performance as measured by ATP production and electroretinogram (ERG). 11,12,14,19,20 Although enhanced photoreceptor function shown in ERG is reported in diabetic mouse models, the same models suggest the complex IV direct and indirect pathways may not mediate the effect. [21][22][23] Confounders, such as severity of hyperglycemia, might explain this result.…”

Section: Mechanism Of Actionmentioning

confidence: 99%

See 2 more Smart Citations

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review

Muste¹,

Russell²,

Singh³

2021

OPTH

View full text Add to dashboard Cite

Purpose Photobiomodulation therapy (PBT) has emerged as a possible treatment for age-related macular degeneration (AMD) and diabetic retinopathy (DR). This review seeks to summarize the application of PBT in AMD and DR. Methods The National Clinical Trial (NCT) database and PubMed were queried using a literature search strategy and reviewed by the authors. Results Fourteen studies examining the application of PBT for AMD and nine studies examining the application of PBT for diabetic macular edema (DME) were extracted from 60 candidate publications. Discussion Despite notable methodological differences between studies, PBT has been reported to treat certain DR and AMD patients. DR patients with center involving DME and VA ≥ 20/25 have demonstrated response to treatment. AMD patients at Age-Related Eye Disease Study Stages 2–4 with VA ≥20/200 have also shown response to treatment. Results of major clinical trials are pending. Conclusion PBT remains an emergent therapy with possible applications in DR and AMD. Further, high powered studies monitored by a neutral party with standard devices, treatment delivery and treatment timing are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Mechanism Of Actionmentioning

confidence: 99%

Section: Mechanism Of Actionmentioning

confidence: 99%

See 1 more Smart Citation

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review

Muste¹,

Russell²,

Singh³

2021

OPTH

View full text Add to dashboard Cite

show abstract

“…Again, the aim is to improve RPE metabolic activity and slow AMD progression. 66 Some studies have reported positive effects of photobiomodulation on intermediate AMD. LIGHTSITE II was a prospective clinical trial, completed in 2021, that assessed the efficacy of photobiomodulation in dry AMD (ClinicalTrials.gov NCT03878420).…”

Section: Conbercept (Chengdumentioning

confidence: 99%

Towards the Development of Longer and More Efficacious Therapies for Wet and Dry Age-related Macular Degeneration

Arrigo¹,

Bandello²

2022

US Ophthalmic Review

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is a leading cause of vision loss in developed countries. The advanced stages of AMD are characterized by the onset and progression of macular neovascularization or geographic atrophy. Several treatments are currently available for managing the neovascular form of AMD, based on intravitreal anti-vascular endothelial growth factor (anti-VEGF) drugs. Although these agents are efficient in inducing fluid regression and preserving visual function, their limited duration of action and treatment burden are stimulating the development of new molecules with more prolonged pharmacological activity. The future of exudative AMD therapies will include new generations of anti-VEGF drugs, surgical anti-VEGF port delivery systems and novel molecules acting on other AMD pathogenic pathways. In contrast, dry AMD and geographic atrophy have no approved treatments; nutraceutical approaches still represent the only way to reduce the probability of AMD progression and the onset of complications. Several ongoing clinical trials are testing different molecules that have been developed to slow the progression of geographic atrophy, including complement system inhibitors, integrin inhibitors, gene therapies and cell-based therapies. In this review, we provide an overview of the current state of the art and future perspectives for the management of dry and wet AMD.

show abstract

“…It has been demonstrated that PBM at 670 nm increased mitochondrial membrane potential and reduced complement activity in the aging retina [82][83][84][85]. Studies have shown that PBM can improve visual acuity, contrast sensitivity, and fixation stability, reduce drusen volume and thickness, and has beneficial effects on macular pigment density but no adverse side effects in patients with AMD [86][87][88][89][90][91].…”

Section: Ophthalmological Applications Of Pbmmentioning

confidence: 99%

Photobiomodulation therapy in ophthalmology

Zadorozhnyy¹,

Korol²,

Nasinnyk³

et al. 2022

Oftalmol Zh

View full text Add to dashboard Cite

SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine) Photobiomodulation (PBM) therapy is a form of light therapy that utilizes non-ionizing forms of light sources in the far-red to near-infrared spectrum to produce non-thermal photochemical reactions in different biological structures. The paper reviews the experience of implementing (a) PBM in different fields of medicine (e.g., ophthalmology) and (b) the known mechanisms of PBM-induced effects on cells and tissues.

show abstract

Photobiomodulation therapy in age-related macular degeneration

Abstract: Purpose of reviewTo review the available data supporting the use of photobiomodulation therapy (PBT) in the treatment of age-related macular degeneration (AMD).

Cited by 8 publications

References 33 publications

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review

Towards the Development of Longer and More Efficacious Therapies for Wet and Dry Age-related Macular Degeneration

Photobiomodulation therapy in ophthalmology

Contact Info

Product

Resources

About